The FDA approved venetoclax (Venclexta, AbbVie/Genentech) for the treatment of adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including those who have not received previous treatment.
The approval was based on the randomized, multicenter CLL14 trial (ClinicalTrials.gov Identifier: NCT02242942). During this open-label, active-controlled trial, investigators compared venetoclax plus obinutuzumab (Gazyva, Genentech) with chlorambucil plus obinutuzumab in 432